---
title: "Buy Rating Maintained on YARTEMLEA as Analyst Trims Price Target to $33 but Sees U.S. Launch Driving Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290986837.md"
description: "H.C. Wainwright analyst Brandon Folkes maintains a Buy rating on Omeros, lowering the price target to $33 from previous levels. The adjustment reflects conservative assumptions following a negative European CHMP opinion for YARTEMLEA, though Folkes views this as short-term pressure. He emphasizes that the U.S. launch remains the primary value driver. Upcoming milestones, including U.S. sales data and progress in the TA-TMA program, support the favorable risk-reward profile justifying the continued Buy recommendation."
datetime: "2026-06-26T15:35:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290986837.md)
  - [en](https://longbridge.com/en/news/290986837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290986837.md)
generator: "portal-rs"
---

# Buy Rating Maintained on YARTEMLEA as Analyst Trims Price Target to $33 but Sees U.S. Launch Driving Upside

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Omeros, with a price target of $33.00.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Brandon Folkes has given his Buy rating due to a combination of factors centered on YARTEMLEA’s U.S. potential, even after the recent European setback. He views the negative CHMP opinion as creating short-term pressure rather than undermining the overall investment case, noting that the removal of Europe from his model only modestly trims his valuation and that the U.S. launch remains the key driver of future value.

He also highlights that his revised $33 price target reflects more conservative assumptions, including eliminating the EU contribution, applying a lower exit multiple, and raising projected R&D spending, yet still implies meaningful upside from current levels. In his view, upcoming milestones such as initial U.S. YARTEMLEA sales data, results from the Alexion/AstraZeneca TA-TMA program, and potential progress toward an additional $100 million milestone support a favorable risk‑reward profile that justifies maintaining a Buy recommendation.

Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Connect Biopharma Holdings, and Omeros. According to TipRanks, Folkes has an average return of -1.3% and a 39.76% success rate on recommended stocks.

### Related Stocks

- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)
- [CNTB.US](https://longbridge.com/en/quote/CNTB.US.md)

## Related News & Research

- [Insider Shake-Up at Omeros as Key Director Sells Off a Chunk of Shares](https://longbridge.com/en/news/296662749.md)
- [Omeros director Joseph L. Schocken files initial beneficial ownership statement](https://longbridge.com/en/news/296288452.md)
- [Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/295993093.md)
- [Omeros director Thomas J. Cable disposes of 15,000 common shares for $276,772.50](https://longbridge.com/en/news/296655425.md)
- [Omeros VP Finance, CAO David J. Borges sells 5,000 shares worth $84,750](https://longbridge.com/en/news/296155281.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**